Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):
 
May 14, 2018
jnjlogoa06a02a01a01a01a20.jpg
 
(Exact name of registrant as specified in its charter)
 
 
New Jersey
I-3215
22-1024240
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)


One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933
 
(Address of Principal Executive Offices)
 (Zip Code)
 
Registrant's telephone number, including area code:
732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
               CFR 240.14d-2(b))
 
o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
               CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



 
 


 
Item 7.01             Regulation FD Disclosure
 
On April 17, 2018, Johnson & Johnson furnished supplemental sales information related to the Cerenovus business. The 2016 sales information below has been revised to reclassify $156 million from Orthopaedics to Interventional Solutions.
 
Johnson & Johnson
Supplemental Sales Information
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
Prior quarter amounts have been reclassified to
conform to current quarter product disclosure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2016
 
2017
 
 
Full Year
 
Q1
 
Q2
 
Q3
 
Q4
MEDICAL DEVICES SEGMENT (1)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTERVENTIONAL SOLUTIONS (2)
 
 
 
 
 
 
 
 
 
 
US
$
1,031

 
         279
 
         285
 
         279
 
         305
Intl
 
1,024

 
         270
 
         288
 
         274
 
         316
WW
 
2,055

 
         549
 
         573
 
         553
 
         621
 
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS (2)
 
 
 
 
 
 
 
 
 
 
US
 
5,438

 
      1,359
 
      1,367
 
      1,308
 
      1,370
Intl
 
3,690

 
         916
 
         926
 
         896
 
         916
WW
 
9,128

 
      2,275
 
      2,293
 
      2,204
 
      2,286
SPINE & OTHER  (2)
 
 
 
 
 
 
 
 
 
 
US
 
2,152

 
         513
 
         533
 
         495
 
         512
Intl
 
1,522

 
         370
 
         382
 
         376
 
         344
WW
$
3,674

 
         883
 
         915
 
         871
 
         856
 
 
 
 
 
 
 
 
 
 
 
(1) Quarterly data unaudited
 
 
 
 
 
 
 
 
 
 
(2) All sales related to the Cerenovus business were reclassified to Interventional Solutions (previously referred to as Cardiovascular); The
Cerenovus business includes the Codman Neurovascular business as well as the recent acquisitions of Neuravi and Pulsar (previously
included in Spine & Other in Orthopaedics).


















SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Johnson & Johnson
 
 
 
 (Registrant)
 
 
 
 
Date: May 14, 2018
By:
/s/ Ronald A. Kapusta
 
 
 
Ronald A. Kapusta
Controller
(Principal Accounting Officer)